We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+89.28%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
+$188M
Cap. Flow
+$206M
Cap. Flow %
41.36%
Top 10 Hldgs %
50.9%
Holding
101
New
48
Increased
19
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$44.5M
2
DNLI icon
Denali Therapeutics
DNLI
+$14.8M
3
BHVN icon
Biohaven
BHVN
+$12.3M
4
WVE icon
Wave Life Sciences
WVE
+$9.79M
5
ARGX icon
argenx
ARGX
+$8.22M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.6M
2
MRUS
Merus
MRUS
+$14M
3
ACLX
Arcellx
ACLX
+$13.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$3.76B
$6M 1.2%
+474,612
New +$5.41M
MLYS icon
27
Mineralys Therapeutics
MLYS
$2.39B
$6M 1.2%
158,112
-473,474
-75% -$10.2M
AKRO
28
DELISTED
Akero Therapeutics
AKRO
$5.76M 1.16%
121,410
+4,631
+4% +$224K
JAZZ icon
29
Jazz Pharmaceuticals
JAZZ
$15.2B
$5.15M 1.03%
+39,072
New +$4.69M
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$4.97M 1%
+114,053
New +$4.61M
NAMS icon
31
NewAmsterdam Pharma
NAMS
$3.63B
$4.28M 0.86%
150,573
-2,079
-1% -$49.8K
OCUL icon
32
Ocular Therapeutix
OCUL
$2.01B
$4.2M 0.84%
+359,470
New +$4.3M
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$12.6B
$3.76M 0.75%
8,207
-44,487
-84% -$16.6M
AMLX icon
34
Amylyx Pharmaceuticals
AMLX
$1.89B
$3.76M 0.75%
+276,884
New +$2.61M
INCY icon
35
Incyte
INCY
$23.3B
$3.71M 0.74%
+43,754
New +$3.46M
GPCR icon
36
Structure Therapeutics
GPCR
$3.27B
$3.62M 0.73%
+129,335
New +$2.58M
TRVI icon
37
Trevi Therapeutics
TRVI
$2.46B
$3.21M 0.64%
+350,710
New +$2.63M
PTGX icon
38
Protagonist Therapeutics
PTGX
$8.49B
$3.19M 0.64%
47,954
+31,184
+186% +$1.77M
NKTR icon
39
Nektar Therapeutics
NKTR
$2.27B
$3.03M 0.61%
+53,201
New +$1.76M
ASND icon
40
Ascendis Pharma A/S
ASND
$17B
$3.01M 0.6%
+15,149
New +$2.83M
TECX
41
Tectonic Therapeutic
TECX
$578M
$2.97M 0.59%
188,999
+148,999
+372% +$3.08M
HROW icon
42
Harrow
HROW
$1.67B
$2.78M 0.56%
+57,619
New +$2.17M
TSHA icon
43
Taysha Gene Therapies
TSHA
$1.72B
$2.75M 0.55%
839,669
-364,272
-30% -$1.03M
EQ icon
44
Equillium
EQ
$158M
$2.73M 0.55%
+1,908,935
New +$2.02M
UTHR icon
45
United Therapeutics
UTHR
$22.5B
$2.63M 0.53%
+6,264
New +$2.11M
CGON icon
46
CG Oncology
CGON
$6.13B
$2.54M 0.51%
+63,019
New +$1.83M
QQQ icon
47
Invesco QQQ Trust
QQQ
$466B
$2.28M 0.46%
+3,797
New +$2.17M
BBOT
48
BridgeBio Oncology
BBOT
$666M
$2.16M 0.43%
186,614
-129,198
-41% -$1.35M
TNGX icon
49
Tango Therapeutics
TNGX
$4.5B
$2.06M 0.41%
245,378
+36,578
+18% +$248K
ORIC icon
50
Oric Pharmaceuticals
ORIC
$1.11B
$2M 0.4%
166,461
-34,324
-17% -$361K
1
2
3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Stempoint Capital held 101 positions worth $499M, up 60% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $206M of net new capital in Q3 2025, opening 48 new positions and adding to 19 existing holdings. Its largest new stake was argenx: 12,465 shares worth $9.19M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $16.6M trimmed.

  • Stempoint Capital's largest Q3 2025 buy was argenx: 12,465 shares worth $9.19M.
  • Stempoint Capital added most to Roivant Sciences in Q3 2025, an estimated $44.5M increase.
  • Stempoint Capital's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $16.6M.
  • Stempoint Capital fully exited Merus in Q3 2025, selling an estimated $14M.
  • Stempoint Capital's ten largest holdings make up 51% of its $499M portfolio in Q3 2025.
  • Stempoint Capital opened 48 new positions and closed 14 in Q3 2025.
  • Stempoint Capital's portfolio value rose 60% quarter-over-quarter to $499M.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.